Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Solvay To Sell Peptisyntha
by Ann M. Thayer
September 2, 2013
| A version of this story appeared in
Volume 91, Issue 35
International Chemical Investors Group will buy Peptisyntha, a custom peptide manufacturer, from Solvay. A specialist in liquid-phase synthesis, Brussels-based Peptisyntha will join other peptide manufacturers within ICIG’s CordenPharma group. In 2011, ICIG purchased Genzyme’s pharmaceutical intermediates business in Switzerland and Roche’s peptide manufacturing site in Colorado. Peptisyntha’s U.S.-based sister company was shut down in March, and some of its customer relationships will be transferred. The peptide sale will complete Solvay’s exit from the life sciences area.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter